AC Immune SA

Equities

ACIU

CH0329023102

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 28/05/2024 BST			5-day change	1st Jan Change
3.87 ^USD	+9.32%		+15.87%	-22.60%

05-13	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
05-13	Sector Update: Health Care	MT

AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2024

May 13, 2024 at 11:05 am

AC Immune SA reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was CHF 17.86 million compared to CHF 17.51 million a year ago. Basic loss per share from continuing operations was CHF 0.18 compared to CHF 0.21 a year ago.

Latest news about AC Immune SA

Sector Update: Health Care Stocks Mixed Late Afternoon	05-13	MT
Sector Update: Health Care	05-13	MT
Top Midday Gainers	05-13	MT
AC Immune Enters Licensing Deal for Alzheimer's Disease Drug Candidate	05-13	MT
Wall Street Set to Open Higher Monday as Investors Look Toward Key Inflation Figures	05-13	MT
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday Ahead of Key Inflation Reports	05-13	MT
Investors Eye Key Inflation Data in Days Ahead as US Futures Trend Modestly Higher Monday	05-13	MT
Top Premarket Gainers	05-13	MT
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate	05-13	MT
AC Immunity Shares Soar on Exclusive License Deal with Takeda	05-13	DJ
AC Immune SA Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
AC Immune Files $350 Million Mixed Shelf	03-15	MT
AC Immune SA Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Certain Common Shares of AC Immune SA are subject to a Lock-Up Agreement Ending on 14-FEB-2024.	02-13	CI
AC Immune to Regain Global Rights of Crenezumab, Semorinema	01-22	MT
Roche terminates licensing agreement with AC Immune	01-22	CF
AC Immune SA Announces Termination of the Research Collaboration and License Agreement with Genentech, Inc	01-22	CI
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson's Diseases	01-03	CI
AC Immune SA(NasdaqGM:ACIU) added to NASDAQ Biotechnology Index	12-18	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	12-15	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	12-15	MT
AC Immune SA Announces its Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial	12-15	CI
AC Immune to Launch Mid-Stage Trial of Alzheimer's Disease Therapy; Prices $50.1 Million Common Stock Offering; Shares Rise	12-15	MT
AC Immune Officially Names Christopher Roberts as CFO	12-01	MT
AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024	12-01	CI

Chart AC Immune SA

Duration

Period

More charts

Company Profile

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimerâs disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Sector

Biotechnology & Medical Research

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for AC Immune SA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.236 CHF

Average target price

9.984 CHF

Spread / Average Target

+208.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AC IMMUNE SA	-22.60%	333M
MODERNA, INC.	+54.05%	63.85B
IQVIA HOLDINGS INC.	-2.02%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.69B
BIO-TECHNE CORPORATION	+2.89%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.40%	12.11B
MEDPACE HOLDINGS, INC.	+27.49%	12.07B

Other Biotechnology & Medical Research